Renal news roundup from AKF

A panel of FDA advisers voted 9-4 to recommend approval of Ardelyx's chronic kidney disease (CKD) drug Xphozah, or tenapanor, as a monotherapy for treating...

BioPorto has filed a De Novo application with the FDA for its neutrophil gelatinase-associated lipocalin (NGAL) test for acute kidney injury (AKI) diagnosis. Th...

Provention Bio's monoclonal antibody drug teplizumab is the first treatment to receive FDA approval for delaying the onset of insulin-dependent type 1 diab...

Research involving 150 Black adults with hypertension and chronic kidney disease found that nutrition coaching was better than a food subsidy alone for improvem...

A study presented at the American Society of Nephrology's Kidney Week 2022 found that patients with type 2 diabetes and chronic kidney disease who were tre...

Patients with type 2 diabetes and obesity who have low muscle mass also had a greater risk for incident chronic kidney disease (CKD), according to a study publi...

Researchers examined 188,671 adults with kidney failure initiating dialysis, and found that Affordable Care Act (ACA) Medicaid expansion was tied to a reduction...

A study published in JAMA Network Open found employer-based commercial health plans spend about $238,126 for the first year of dialysis treatments for their ben...

A study involving 745 Asian adults receiving hemodialysis found that a severely high parathyroid hormone level correlated with low serum albumin levels, which a...